Sarina Tanimoto Sells 100,000 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) insider Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total value of $1,316,000.00. Following the sale, the insider now directly owns 1,148,499 shares in the company, valued at approximately $15,114,246.84. This trade represents a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Sarina Tanimoto also recently made the following trade(s):

• On Tuesday, October 15th, Sarina Tanimoto sold 100,000 shares of ARS Pharmaceuticals stock. The stock was sold at an average price of $14.88, for a total value of $1,488,000.00.

ARS Pharmaceuticals Stock Down 5.9 %

Shares of SPRY opened at $11.90 on Friday. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -23.33 and a beta of 0.88. ARS Pharmaceuticals, Inc. has a 12 month low of $5.02 and a 12 month high of $18.51. The company has a 50-day moving average price of $14.62 and a two-hundred day moving average price of $12.34.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. J.W. Cole Advisors Inc. raised its stake in shares of ARS Pharmaceuticals by 10.8% in the second quarter. J.W. Cole Advisors Inc. now owns 15,400 shares of the company’s stock valued at $131,000 after acquiring an additional 1,500 shares during the last quarter. nVerses Capital LLC bought a new position in shares of ARS Pharmaceuticals in the third quarter valued at approximately $30,000. Creative Planning raised its stake in shares of ARS Pharmaceuticals by 7.0% in the third quarter. Creative Planning now owns 35,263 shares of the company’s stock valued at $511,000 after acquiring an additional 2,307 shares during the last quarter. HighTower Advisors LLC raised its stake in shares of ARS Pharmaceuticals by 18.2% in the third quarter. HighTower Advisors LLC now owns 28,310 shares of the company’s stock valued at $411,000 after acquiring an additional 4,369 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ARS Pharmaceuticals by 151.7% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,419 shares of the company’s stock valued at $63,000 after acquiring an additional 4,472 shares during the last quarter. Institutional investors own 68.16% of the company’s stock.

Wall Street Analyst Weigh In

SPRY has been the topic of a number of recent research reports. Leerink Partners lifted their target price on ARS Pharmaceuticals from $21.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 20th. William Blair upgraded shares of ARS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $30.00 price target on shares of ARS Pharmaceuticals in a research note on Tuesday, October 8th. Four analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $24.00.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.